摘要
福辛普利（蒙诺）是其活性二价酸福辛普利拉的酯类前体药物，也是新的磷酸类血管紧张素转换酶（ＡＣＥ）抑制剂家族中的第一个成员。与其它ＡＣＥ抑制剂一样，福辛普利主要通过阻断血管紧张素Ⅱ的形成而降低血压，该药物在原发性高血压和心力衰竭等患者中已显示其临床效果。在ＡＣＥ抑制剂中，福辛普利的特点是具有肝脏、肾脏双重清除途径，两者之间能保持平衡。研究表明，对于患慢性心力衰竭，并同时患有肾脏功能不全的患者来说，福辛普利可能是一种可与其它ＡＣＥ抑制剂相替换的有价值的药物。
Fosinopril (MoNopril) is an ester pro-drug of the active Daicel fosinoprilat and is the first member of a new class of angiotensin-converting enzyme (ACE) inhibitors, the phosphoric acids. Like other ACE inhibitors, Fosinopril reduces blood pressure primarily by blocking the formation of angiotensin and has shown clinical efficacy in patients with essential hypertension and congestive heart failure. Fosinopril is unique amongst ACE inhibitors in having a dual route of eliminating that is balanced between the liver and the kidneys, which suggested that fosinopril may be a valuable alternative to other ACE inhibitors in patients with chronic heart failure and concurrent renal insufficiency.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2000年第1期66-68,共3页
The Chinese Journal of Clinical Pharmacology
